JP4615866B2 - Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形 - Google Patents

Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形 Download PDF

Info

Publication number
JP4615866B2
JP4615866B2 JP2003583994A JP2003583994A JP4615866B2 JP 4615866 B2 JP4615866 B2 JP 4615866B2 JP 2003583994 A JP2003583994 A JP 2003583994A JP 2003583994 A JP2003583994 A JP 2003583994A JP 4615866 B2 JP4615866 B2 JP 4615866B2
Authority
JP
Japan
Prior art keywords
nateglinide
solvent
crystalline form
crystals
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003583994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522503A (ja
JP2005522503A5 (enExample
Inventor
ポール・アレン・サットン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2005522503A publication Critical patent/JP2005522503A/ja
Publication of JP2005522503A5 publication Critical patent/JP2005522503A5/ja
Application granted granted Critical
Publication of JP4615866B2 publication Critical patent/JP4615866B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003583994A 2002-04-15 2003-04-14 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形 Expired - Fee Related JP4615866B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37262502P 2002-04-15 2002-04-15
PCT/EP2003/003864 WO2003087038A1 (en) 2002-04-15 2003-04-14 Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010156749A Division JP2010265295A (ja) 2002-04-15 2010-07-09 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形

Publications (3)

Publication Number Publication Date
JP2005522503A JP2005522503A (ja) 2005-07-28
JP2005522503A5 JP2005522503A5 (enExample) 2006-06-01
JP4615866B2 true JP4615866B2 (ja) 2011-01-19

Family

ID=29250881

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003583994A Expired - Fee Related JP4615866B2 (ja) 2002-04-15 2003-04-14 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形
JP2010156749A Pending JP2010265295A (ja) 2002-04-15 2010-07-09 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010156749A Pending JP2010265295A (ja) 2002-04-15 2010-07-09 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形

Country Status (8)

Country Link
US (3) US7247746B2 (enExample)
EP (1) EP1497258A1 (enExample)
JP (2) JP4615866B2 (enExample)
CN (1) CN1304366C (enExample)
AU (1) AU2003242520A1 (enExample)
BR (1) BR0309210A (enExample)
CA (1) CA2482669A1 (enExample)
WO (1) WO2003087038A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
WO2004020396A1 (en) * 2002-08-28 2004-03-11 Dr. Reddy's Laboratories Limited Crystalline form of nateglinide and process for preparation thereof
US7449519B2 (en) * 2003-02-18 2008-11-11 Konishi Co., Ltd. Curing resin, method for producing same and curing resin composition
HU227073B1 (hu) * 2003-07-10 2010-06-28 Richter Gedeon Nyrt Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
JP2015522531A (ja) 2012-05-07 2015-08-06 セリックスビオ プライヴェート リミテッド 神経筋疾患及び神経変性疾患の治療のための組成物及び方法
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
WO2013167987A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of diabetes
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
CN107207411A (zh) 2014-12-01 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
CN109100430A (zh) * 2017-06-20 2018-12-28 珠海同益制药有限公司 一种那格列奈手性异构体色谱分析方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DE69217762T2 (de) * 1991-07-30 1997-10-09 Ajinomoto Kk Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
EP1435912A4 (en) 2001-09-12 2005-03-30 Alembic Ltd NOVEL STABLE CRYSTAL FORM OF N- (TRANS-4-ISOPROPYLCYCLOHEXYL CARBONYL) -D-PHENYLALANINE AND PREPARATION METHOD THEREOF
WO2003087039A1 (en) * 2002-04-15 2003-10-23 Ajinomoto Co., Inc. Novel nateglinide crystal

Also Published As

Publication number Publication date
EP1497258A1 (en) 2005-01-19
AU2003242520A1 (en) 2003-10-27
CN1646481A (zh) 2005-07-27
CA2482669A1 (en) 2003-10-23
JP2005522503A (ja) 2005-07-28
CN1304366C (zh) 2007-03-14
US20080319222A1 (en) 2008-12-25
US7247746B2 (en) 2007-07-24
US20050256336A1 (en) 2005-11-17
WO2003087038A1 (en) 2003-10-23
US20080081927A1 (en) 2008-04-03
BR0309210A (pt) 2005-02-09
JP2010265295A (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
JP2005522503A (ja) Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形
US5463116A (en) Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
EP0526171B1 (en) Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them
JP5305248B2 (ja) 新規ナテグリニド結晶
JP2002519422A (ja) パロキセチンメタンスルホネート
JP2003513062A (ja) 塩酸セルトラリンの多形形態
KR20250113526A (ko) 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
IL101358A (en) Crystalline tiagabine hydrochloride monohydrate its preparation and pharmaceutical composition containing it
JP2019523273A (ja) ベリノスタットの多形形態、およびその調製のためのプロセス
WO2016150349A1 (zh) 一种pci-32765晶型a的制备方法
US7977507B2 (en) Nateglinide crystals
TWI870559B (zh) 一種製造2-[(4s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-4h-喹唑啉-4-基]乙酸鈉三水合物之結晶型之方法
JP3190679B2 (ja) 複素環式化学
JPH06192228A (ja) 結晶性（ｒ）−（−）−２−シクロヘプチル−ｎ−メチルスルフオニル−［４−（２−キノリニルメトキシ）−フエニル］−アセトアミド
CN117088925A (zh) 一种化合物晶型及其制备、组合物和用途
CN105992769A (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
JP2007510715A (ja) アトバコンの新規な多形およびその調製のプロセス
JP3001975B2 (ja) 結晶性チアガビン塩酸塩−水和物、その製造方法および用途
WO2025040154A1 (zh) 一种化合物晶型及其制备、组合物和用途
CN117980295A (zh) 一种依洛西巴特晶型ii及其制备方法
WO2025083656A1 (en) Novel crystalline form of lenacapavir sodium and processes for its preparation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060410

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100709

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101012

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101021

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131029

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees